U.S., July 11 -- ClinicalTrials.gov registry received information related to the study (NCT07695298) titled 'A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome' on July 06.
Brief Summary: This study will evaluate the safety and effects, good or bad of faricimab (Vabysmo(R)), a drug that is approved by the U.S. Food and Drug Administration (FDA) for other retinal conditions, but its use is considered investigational when used specifically for choroidal neovascularization (CNV) related to presumed ocular histoplasmosis (POHS)
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Presumed Ocular Histoplasmosis
Intervention:
DRUG: Faricim...